Vertex Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Vertex Pharmaceuticals has a total shareholder equity of $14.8B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $20.1B and $5.4B respectively. Vertex Pharmaceuticals's EBIT is $4.2B making its interest coverage ratio -6.5. It has cash and short-term investments of $5.8B.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | -6.5x |
| Cash | US$5.80b |
| Equity | US$14.77b |
| Total liabilities | US$5.36b |
| Total assets | US$20.13b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: VX1's short term assets ($8.9B) exceed its short term liabilities ($3.5B).
Long Term Liabilities: VX1's short term assets ($8.9B) exceed its long term liabilities ($1.8B).
Debt to Equity History and Analysis
Debt Level: VX1 is debt free.
Reducing Debt: VX1 had no debt 5 years ago.
Debt Coverage: VX1 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: VX1 has no debt, therefore coverage of interest payments is not a concern.